Cancer treatment with dendritic cell vaccine Cancerax

Relatively recently, immunotherapy has become a real breakthrough in the treatment of malignant tumors. Thanks to the found mechanisms of influence on the immune system, patients with an oncological diagnosis today can live a long, fulfilling life. That is, cancer has evolved from a “deadly disease” to a chronic disease that can be controlled.

One of the disadvantages of immunotherapy abroad is the high cost, so not all patients have access to innovative technologies. Few people know that there is an opportunity to undergo such treatment in Ukraine, and it costs much less than in Europe and the USA.

The National Cancer Institute has developed a cancer vaccine based on dendritic cells. This technique has a high degree of effectiveness, especially if treatment is started in the early stages of cancer.

What is the principle of action of the Ukrainian dendritic cell vaccine Cancerax?

The Cancerax vaccine is made from the patient’s own tumor material and dendritic cells. To understand how it works, you need to know the basics of how the immune system works.

Doctors call dendritic cells the conductors of the immunological orchestra. The formation of an antigen-specific response is impossible without them. Developing in the body, the tumor produces antigens – specific proteins that the immune system is able to recognize. However, for this to happen, these proteins must be taken up by dendritic cells. They process antigens and present them to T-lymphocytes – killer cells that recognize and kill cancer cells. Without dendritic cells, T-lymphocytes remain “blind” and do not respond to the development of cancer.

The main problem in the treatment of cancer is that the tumor is able to defend itself against the immune system. And one of these mechanisms is the suppression of dendritic cells. The tumor disrupts the process of their maturation, activity, ability to migrate to the lymph nodes and other functions.

To overcome this obstacle, the scientists decided to grow dendritic cells in the laboratory. This is necessary to protect them from the negative effects of the malignant process and to maintain the necessary immunological properties.

The main steps in the manufacture of a dendritic cell vaccine Cancerax against cancer

Treatment consists of the following steps:

• Blood sampling from the patient (the amount may vary depending on the type of vaccine being made).
• Isolation of dendritic progenitor cells using special equipment.
• Maturation of dendritic cells with simultaneous loading of their tumor antigens obtained from a sample of malignant tissue taken from a patient.
• Additional treatment of cells with B. subtilis B-7025 cytotoxic lectins to enhance the immune response.
• Administering a vaccine to a patient.

After entering the body, the antitumor vaccine activates other dendritic cells located at the injection site. Then all cells migrate to the nearest lymph node, where they contact T-lymphocytes, presenting them with tumor antigens. “Trained” killer cells begin to multiply intensively. After that, they are sent to the focus of the malignant process, where they actively search for and destroy cancer cells.

Cancerax dendritic vaccine indications

Treatment is prescribed for patients with various types of malignant neoplasms in the early stages of development. To undergo treatment, the presence of tumor material is necessary. This may be a recently removed tumor or a sample of malignant tissue stored in the right conditions. If a sample is not available, it is possible to isolate circulating tumor cells from the bloodstream.

Important! Vaccine therapy does not replace standard cancer treatment with chemotherapy or radiotherapy. The use of Cancerax dendritic cell vaccine as part of complex therapy minimizes the likelihood of disease recurrence, thereby ensuring a high level of patient survival.